WGU D116 Advanced Pharmacology – OA and
Pre-Assessment Exam Guide (2026/2027)
Section I: Pharmacokinetics & Pharmacodynamics (Questions 1–25)
1. Which pharmacokinetic process describes the movement of a drug from its site of
administration into the systemic circulation?
A) Distribution
B) Metabolism
C) Absorption
D) Excretion
Correct Answer: C
Rationale: Absorption is the first phase of pharmacokinetics and refers to the transfer of a
medication from its administration site into the bloodstream, where it becomes available for
distribution to tissues . Distribution involves movement from blood to tissues. Metabolism is
enzymatic alteration. Excretion is removal from the body.
2. A medication has a bioavailability of 25%. What does this indicate about the drug?
A) 75% of the drug is bound to plasma proteins
B) Only 25% of the administered dose reaches systemic circulation unchanged
C) 25% of the drug is excreted unchanged in the urine
D) The drug has a therapeutic index of 25
Correct Answer: B
Rationale: Bioavailability (F) represents the fraction of an administered dose that reaches
systemic circulation in unchanged, active form . A value of 25% indicates that 75% of the dose
is lost before reaching systemic circulation—typically due to incomplete absorption or first-
pass metabolism.
3. A patient with severe hypoalbuminemia is prescribed a highly protein-bound medication.
Which effect is most likely?
,A) Decreased drug absorption from the GI tract
B) Increased proportion of free, pharmacologically active drug
C) Decreased renal elimination of the drug
D) Complete failure of drug distribution
Correct Answer: B
Rationale: Only unbound drug is pharmacologically active and able to cross membranes to
reach target receptors . When albumin is reduced, fewer binding sites are available, leading to
an increased free fraction of the drug, which can intensify therapeutic effects and increase
toxicity risk .
4. Which statement best describes the difference between pharmacokinetics and
pharmacodynamics?
A) Pharmacokinetics describes what the body does to a drug, while pharmacodynamics
describes what a drug does to the body
B) Pharmacokinetics describes drug-receptor interactions, while pharmacodynamics describes
drug absorption
C) Pharmacokinetics and pharmacodynamics are interchangeable terms for drug metabolism
D) Pharmacokinetics describes drug toxicity, while pharmacodynamics describes drug efficacy
Correct Answer: A
Rationale: Pharmacokinetics (PK) encompasses Absorption, Distribution, Metabolism, and
Excretion—"what the body does to the drug." Pharmacodynamics (PD) describes the
biochemical and physiologic effects of drugs and their mechanisms of action—"what the drug
does to the body" .
5. A drug that strongly inhibits CYP3A4 is co-administered with another drug metabolized by
CYP3A4. What is the most likely outcome for the second drug?
A) Decreased plasma concentration due to faster metabolism
B) Increased plasma concentration with potential toxicity
C) No change in plasma concentration
D) Increased renal excretion of the second drug
Correct Answer: B
, Rationale: Inhibition of CYP450 enzymes reduces the metabolism of substrate drugs,
causing their plasma concentrations to rise . This can lead to toxic effects. CYP3A4 metabolizes
approximately 50% of all drugs, making this interaction clinically significant.
6. Which route of administration completely bypasses the first-pass effect?
A) Oral
B) Sublingual
C) Rectal (lower portion)
D) Enteric-coated oral
Correct Answer: B
Rationale: Sublingual administration allows direct absorption into systemic circulation via
the oral mucosa, bypassing the portal circulation and hepatic first-pass metabolism . This
route is used for nitroglycerin and other drugs requiring rapid onset without hepatic
degradation.
7. A drug has a half-life of 8 hours. Approximately how long will it take to reach steady-state
concentration with repeated dosing?
A) 8 hours
B) 16 hours
C) 32–40 hours
D) 80 hours
Correct Answer: C
Rationale: Steady state is achieved after approximately 4–5 half-lives . For a drug with an
8-hour half-life, steady state occurs at approximately 32–40 hours (4–5 × 8 hours). At steady
state, the rate of drug administration equals the rate of elimination.
8. Which organ is primarily responsible for drug metabolism via cytochrome P450 enzymes?
A) Kidney
B) Liver
C) Lung
D) Spleen
, Correct Answer: B
Rationale: The liver is the major site of drug biotransformation and contains high
concentrations of CYP450 enzymes involved in Phase I metabolism . Hepatic impairment
significantly alters drug metabolism, prolonging half-life and increasing toxicity risk.
9. A drug that binds to a receptor and produces a maximal biological response is classified as
a:
A) Partial agonist
B) Antagonist
C) Full agonist
D) Inverse agonist
Correct Answer: C
Rationale: Full agonists possess both high affinity for the receptor and high intrinsic
activity, meaning they fully activate the receptor to produce a maximal response . Partial
agonists produce submaximal responses. Antagonists block receptor activation without
producing a response.
10. Which factor most significantly affects the absorption of orally administered medications?
A) Renal clearance
B) First-pass metabolism in the liver
C) Volume of distribution
D) Plasma protein binding
Correct Answer: B
Rationale: First-pass metabolism refers to hepatic metabolism of a drug before it reaches
systemic circulation, significantly reducing oral bioavailability . Drugs with extensive first-pass
metabolism (e.g., nitroglycerin, propranolol, morphine) require higher oral doses or
alternative routes.
11. A patient with chronic kidney disease requires a medication primarily excreted renally.
How should the clinician adjust dosing?
Pre-Assessment Exam Guide (2026/2027)
Section I: Pharmacokinetics & Pharmacodynamics (Questions 1–25)
1. Which pharmacokinetic process describes the movement of a drug from its site of
administration into the systemic circulation?
A) Distribution
B) Metabolism
C) Absorption
D) Excretion
Correct Answer: C
Rationale: Absorption is the first phase of pharmacokinetics and refers to the transfer of a
medication from its administration site into the bloodstream, where it becomes available for
distribution to tissues . Distribution involves movement from blood to tissues. Metabolism is
enzymatic alteration. Excretion is removal from the body.
2. A medication has a bioavailability of 25%. What does this indicate about the drug?
A) 75% of the drug is bound to plasma proteins
B) Only 25% of the administered dose reaches systemic circulation unchanged
C) 25% of the drug is excreted unchanged in the urine
D) The drug has a therapeutic index of 25
Correct Answer: B
Rationale: Bioavailability (F) represents the fraction of an administered dose that reaches
systemic circulation in unchanged, active form . A value of 25% indicates that 75% of the dose
is lost before reaching systemic circulation—typically due to incomplete absorption or first-
pass metabolism.
3. A patient with severe hypoalbuminemia is prescribed a highly protein-bound medication.
Which effect is most likely?
,A) Decreased drug absorption from the GI tract
B) Increased proportion of free, pharmacologically active drug
C) Decreased renal elimination of the drug
D) Complete failure of drug distribution
Correct Answer: B
Rationale: Only unbound drug is pharmacologically active and able to cross membranes to
reach target receptors . When albumin is reduced, fewer binding sites are available, leading to
an increased free fraction of the drug, which can intensify therapeutic effects and increase
toxicity risk .
4. Which statement best describes the difference between pharmacokinetics and
pharmacodynamics?
A) Pharmacokinetics describes what the body does to a drug, while pharmacodynamics
describes what a drug does to the body
B) Pharmacokinetics describes drug-receptor interactions, while pharmacodynamics describes
drug absorption
C) Pharmacokinetics and pharmacodynamics are interchangeable terms for drug metabolism
D) Pharmacokinetics describes drug toxicity, while pharmacodynamics describes drug efficacy
Correct Answer: A
Rationale: Pharmacokinetics (PK) encompasses Absorption, Distribution, Metabolism, and
Excretion—"what the body does to the drug." Pharmacodynamics (PD) describes the
biochemical and physiologic effects of drugs and their mechanisms of action—"what the drug
does to the body" .
5. A drug that strongly inhibits CYP3A4 is co-administered with another drug metabolized by
CYP3A4. What is the most likely outcome for the second drug?
A) Decreased plasma concentration due to faster metabolism
B) Increased plasma concentration with potential toxicity
C) No change in plasma concentration
D) Increased renal excretion of the second drug
Correct Answer: B
, Rationale: Inhibition of CYP450 enzymes reduces the metabolism of substrate drugs,
causing their plasma concentrations to rise . This can lead to toxic effects. CYP3A4 metabolizes
approximately 50% of all drugs, making this interaction clinically significant.
6. Which route of administration completely bypasses the first-pass effect?
A) Oral
B) Sublingual
C) Rectal (lower portion)
D) Enteric-coated oral
Correct Answer: B
Rationale: Sublingual administration allows direct absorption into systemic circulation via
the oral mucosa, bypassing the portal circulation and hepatic first-pass metabolism . This
route is used for nitroglycerin and other drugs requiring rapid onset without hepatic
degradation.
7. A drug has a half-life of 8 hours. Approximately how long will it take to reach steady-state
concentration with repeated dosing?
A) 8 hours
B) 16 hours
C) 32–40 hours
D) 80 hours
Correct Answer: C
Rationale: Steady state is achieved after approximately 4–5 half-lives . For a drug with an
8-hour half-life, steady state occurs at approximately 32–40 hours (4–5 × 8 hours). At steady
state, the rate of drug administration equals the rate of elimination.
8. Which organ is primarily responsible for drug metabolism via cytochrome P450 enzymes?
A) Kidney
B) Liver
C) Lung
D) Spleen
, Correct Answer: B
Rationale: The liver is the major site of drug biotransformation and contains high
concentrations of CYP450 enzymes involved in Phase I metabolism . Hepatic impairment
significantly alters drug metabolism, prolonging half-life and increasing toxicity risk.
9. A drug that binds to a receptor and produces a maximal biological response is classified as
a:
A) Partial agonist
B) Antagonist
C) Full agonist
D) Inverse agonist
Correct Answer: C
Rationale: Full agonists possess both high affinity for the receptor and high intrinsic
activity, meaning they fully activate the receptor to produce a maximal response . Partial
agonists produce submaximal responses. Antagonists block receptor activation without
producing a response.
10. Which factor most significantly affects the absorption of orally administered medications?
A) Renal clearance
B) First-pass metabolism in the liver
C) Volume of distribution
D) Plasma protein binding
Correct Answer: B
Rationale: First-pass metabolism refers to hepatic metabolism of a drug before it reaches
systemic circulation, significantly reducing oral bioavailability . Drugs with extensive first-pass
metabolism (e.g., nitroglycerin, propranolol, morphine) require higher oral doses or
alternative routes.
11. A patient with chronic kidney disease requires a medication primarily excreted renally.
How should the clinician adjust dosing?
